Conventional chondrosarcoma with focal clear cell change:a clinicopathological and molecular analysis by Lam, Suk Wai et al.
  
 University of Groningen
Conventional chondrosarcoma with focal clear cell change
Lam, Suk Wai; van Langevelde, Kirsten; Suurmeijer, Albert J. H.; Cleven, Arjen H. G.; Bovee,
Judith V. M. G.
Published in:
Histopathology
DOI:
10.1111/his.13952
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lam, S. W., van Langevelde, K., Suurmeijer, A. J. H., Cleven, A. H. G., & Bovee, J. V. M. G. (2019).
Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Histopathology, 75(6), 843-852. https://doi.org/10.1111/his.13952
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-01-2020
Conventional chondrosarcoma with focal clear cell change: a
clinicopathological and molecular analysis
Suk Wai Lam,1 Kirsten van Langevelde,2 Albert J H Suurmeijer,3 Arjen H G Cleven1
& Judith V M G Bovee1
1Department of Pathology, 2Department of Radiology, Leiden University Medical Centre, Leiden, and 3Department of
Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, The
Netherlands
Date of submission 29 May 2019
Accepted for publication 10 July 2019
Published online Article Accepted 11 July 2019
Lam S W, van Langevelde K, Suurmeijer A J H, Cleven A H G & Bovee J V M G
(2019) Histopathology 75, 843–852. https://doi.org/10.1111/his.13952
Conventional chondrosarcoma with focal clear cell change: a clinicopathological and
molecular analysis
Aims: Clear cell chondrosarcomas are known to
occasionally contain areas of low-grade conventional
chondrosarcoma; however, the opposite phenomenon
has not yet been described. We identified five cases of
conventional chondrosarcoma alongside clear cell
chondrosarcoma. Here, we report on their clinico-
pathological and molecular characteristics, and inves-
tigate whether these hybrid lesions should be
considered to be a collision tumour, conventional
chondrosarcoma with clear cell change, or clear cell
chondrosarcoma with extensive areas of conventional
chondrosarcoma, as this has clinical implications.
Methods and results: Clinicohistopathological features
were characterised, immunohistochemistry was per-
formed for H3 histone family member 3B (H3F3B), his-
tone H3 trimethylated on lysine 27 (H3K27me3), and
p53, and genetic alterations of IDH1 (encoding isoci-
trate dehydrogenase 1), IDH2 (encoding isocitrate
dehydrogenase 2), TP53 and H3F3B were evaluated.
All five chondrosarcomas consisted predominantly of
areas with conventional chondrosarcoma. Different
grades were found [grade I (n = 1), grade II (n = 2),
and grade III (n = 2)]. Up to 20% of the tumour con-
sisted of classic features of clear cell chondrosarcoma.
Gradual merging between both components was
observed. Molecular analysis of conventional chon-
drosarcoma components revealed an IDH1 c.395G>T,
p.(Arg132Leu) mutation in two cases, and an IDH1
c.394C>T, p.(Arg132Cys) mutation in one case, with
identical IDH mutations in the clear cell chondrosar-
coma counterpart (100%). Two cases were IDH wild-
type. In all cases, none of the components harboured
H3F3B mutations. High-grade tumours had an aggres-
sive course, as three patients died of the disease.
Conclusion: On the basis of clinicopathological char-
acterisation and genetic alterations, it is suggested
that these lesions should be considered to be conven-
tional chondrosarcoma, with clear cell change.
Pathologists should be aware of their existence to
avoid confusion with clear cell chondrosarcoma, ded-
ifferentiated chondrosarcoma, or chondroblastic
osteosarcoma.
Keywords: clear cell chondrosarcoma, conventional chondrosarcoma, IDH1, IDH2
Introduction
Chondrosarcomas constitute a group of malignant
cartilaginous matrix-producing tumours. This group
encompasses neoplasms with diverse morphological
features and clinical behaviours, with conventional
chondrosarcoma being the most common subtype.
Clear cell chondrosarcoma is a rare subtype of chon-
drosarcoma that is histologically characterised by
cells with vesicular nuclei, surrounded by clear cyto-
plasm with distinct cytoplasmic membranes. Often,
prominent trabeculae of woven bone are present. In
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these tumours, zones with conventional low-grade
chondrosarcoma may frequently (~50%) be encoun-
tered, either as large lobules of tumour cartilage sur-
rounded by clear cells or as small inconspicuous foci
among the clear cells.1,2 The opposite phenomenon,
i.e. areas of clear cell chondrosarcoma within conven-
tional chondrosarcoma, has not been reported in the
literature. Conventional central and clear cell chon-
drosarcoma are clearly two different entities: primary
conventional central chondrosarcomas mainly
develop in the thoracic, pelvic and long bones,3
whereas clear cell chondrosarcoma has a predilection
for the epiphysis of long bones, particularly the proxi-
mal femur.1,2 Furthermore, whereas curettage often
leads to local recurrence with a risk of metastasis,
which can occur after extended periods, en-bloc exci-
sion is usually curative in patients with clear cell
chondrosarcoma.4 The prognosis of conventional cen-
tral chondrosarcoma depends greatly on histological
grade, with 10-year survival rates of 83% (grade I),
64% (grade II), and 29% (grade III), and metastases
are often seen in high-grade tumours (grade III:
70%).5 Besides distinct clinical and phenotypic fea-
tures, different alterations are also found at the
molecular level. IDH1 (encoding isocitrate dehydroge-
nase 1) and IDH2 (encoding isocitrate dehydrogenase
2) mutations are frequently (~50%) present in con-
ventional central chondrosarcoma,6,7 whereas clear
cell chondrosarcomas lack IDH1 and IDH2 mutations
(n = 17),8,9 although a H3F3B (encoding H3 histone
family member 3B) p.K36M mutation was found in
one case.10 Here, we describe the clinicopathological
features of five cases of chondrosarcoma with mor-
phological features of conventional chondrosarcoma
alongside areas of classic clear cell chondrosarcoma
encountered in a bone tumour consultation practice.
Molecular analysis of both components was per-
formed in five cases to detect IDH1, IDH2 or H3F3B
mutations, in order to elucidate whether areas with
clear cell chondrosarcoma morphology represent a
phenotypic phenomenon occurring in conventional
chondrosarcoma, represent a collision between two
types of chondrosarcoma, or should be considered to
be clear cell chondrosarcoma with extensive conven-
tional chondrosarcoma areas.
Materials and methods
C A S E S E L E C T I O N
All conventional chondrosarcomas with clear cell
chondrosarcoma features were encountered in a sub-
specialty consultation practice. Clinical and follow-up
data were retrieved from medical records. Surgical
pathology specimens were routinely processed, and
decalcified with EDTA or formic acid, after which
slides were reviewed by an experienced bone and soft
tissue pathologist (J.V.M.G.B.). Cases in which clear
cell chondrosarcoma morphology constituted <50%
of the specimen were included.
R A D I O L O G Y
Magnetic resonance imaging (MRI) scans were
reviewed in our tertiary tumour referral centre. MRI
was performed externally in three cases (cases 1, 2,
and 5) and in the Leiden University Medical Centre
(LUMC) in two cases (cases 3 and 4). The LUMC MRI
tumour protocol included T1-weighted sequences,
fluid-sensitive sequences (T2 fat suppression), a T1
with fat suppression sequence, and a dynamic series
after intravenous gadolinium contrast administration.
For all cases, at least two imaging planes were avail-
able (axial and coronal, or axial and sagittal). Maxi-
mum tumour size was measured on sagittal or
coronal sequences. Tumour signal intensity, perile-
sional bone marrow or soft tissue oedema and
enhancement pattern were assessed. In addition,
homogeneity was studied within the lesions to assess
whether they contained components with different
imaging characteristics on fluid-sensitive sequences.
I M M U N O H I S T O C H E M I S T R Y
Four-micrometre deparaffinised formalin-fixed paraf-
fin-embedded sections were incubated at 60°C. After
antigen retrieval with Tris-EDTA (pH 9.0) at 97°C for
30 min, representative slides containing both compo-
nents were stained for H3F3B K36M (RM193,
1:2000; Sanbio, Uden, The Netherlands), histone H3
trimethylated on lysine 27 (H3K27me3) (C36B11,
1:10; Cell Signaling, Danvers, MA, USA) and p53
(DO-7, 1:2000; Dako, Glostrup, Denmark) with the
Omnis autostainer (Dako) and use of the Envision
FLEX + detection kit (Dako).
M U T A T I O N A N D B I O I N F O R M A T I C A N A L Y S I S
Areas for microdissection and punching were care-
fully selected. To prevent contamination, areas com-
posed of either conventional chondrosarcoma or clear
cell chondrosarcoma features were selected. Areas
where both components merged were avoided. DNA
was isolated with a fully automated tissue prepara-
tion system (Siemens Healthcare Diagnostics, Tarry-
town, NY, USA), as previously described.11 DNA
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 75, 843–852.
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isolation from frozen sections was performed with the
Wizard Genomic DNA Purification Kit (Promega,
Madison, WI, USA), according to the manufacturer’s
instructions. Mutation analysis of IDH1 (exon 4),
IDH2 (exon 4) and H3F3B (exon 2) for cases 1–4
was performed with the multiplex Ampliseq-based
next-generation sequencing (NGS) protocol, by use of
the Custom AmpliSeq Cancer Hotspot Panels v3
(cases 2 and 3), v4 (case 1), and v4b (case 4).12
Bioinformatic analysis was performed as previously
described.12 For case 5, Sanger sequencing was used
for mutation analysis of IDH1 and IDH2, as previ-
ously described.13 If an IDH1 or an IDH2 mutation in
the conventional chondrosarcoma component was
present, further analysis of the clear cell counterpart
was performed.
Results
C L I N I C A L C H A R A C T E R I S T I C S
The clinical findings are shown in Table 1. Two
patients were women and three patients were men.
The median age at diagnosis was 63 years (range,
15–79 years). Tumour size ranged from 35 to
145 mm (mean, 89 mm). The presenting symptom
was pain in most cases. Follow-up data were avail-
able for all patients, with a mean of 20 months
(range, 10–46 months). Three patients died of disease
(time from diagnosis to death range, 10–46 months).
R A D I O L O G I C A L C H A R A C T E R I S T I C S
Three cases occurred in the long bones (case 1, proxi-
mal tibia; case 2, distal femur; case 5, proximal
femur). The tumours had a metaphyseal location
with extension into the epiphysis and diaphysis (case
1; Figure 1A), a metadiaphyseal location (case 5),
and an epiphyseal location with extension into the
metaphysis (case 2; Figure 1B). The iliac bone was
involved in case 3. In case 4, the tumour was located
in the orbit and maxillary sinus, presented with a soft
tissue component, and concerned a recurrence of a
chondrosarcoma of the nose septum. All tumours
were homogeneous and mainly hyperintense on T2-
weighted/fluid-sensitive MRI sequences. After intra-
venous gadolinium contrast administration, a typical
pattern of septonodular enhancement was noted.
None of the cases showed components of different sig-
nal characteristics within the lesions such as to sug-
gest an area of clear cell chondrosarcoma. In four
cases (cases 2–5), soft tissue involvement was pre-
sent. Perilesional bone marrow oedema was present
in four cases (cases 1–3 and 5). High-grade chon-
drosarcoma was the only radiological differential
diagnosis in four cases (cases 1 and 3–5). However,
in case 2, locally aggressive chondroblastoma and
clear cell chondrosarcoma were also considered,
given the epiphyseal location, which is unusual for
conventional chondrosarcoma.
H I S T O P A T H O L O G I C A L C H A R A C T E R I S T I C S
Four patients (cases 1, 3, 4, and 5) underwent a sur-
gical resection with a biopsy prior to the resection,
and one patient (case 2) underwent a curettage. All
biopsies revealed a conventional chondrosarcoma
component, and were graded according to Evans on
a scale of I–III, based on nuclear size, hyperchro-
masia, mitotic figures, and cellularity (Table 1).14,15
No clear cell chondrosarcoma component was
observed. In case 5, dedifferentiated chondrosarcoma
was considered, given the presence of areas with
abrupt transition to atypical spindle cells. Review of
the primary chondrosarcoma of the nose septum
(case 4) did not reveal areas with clear cell chon-
drosarcoma morphology.
All curettage and resection specimens showed mor-
phological features of both conventional chondrosar-
coma and clear cell chondrosarcoma. Conventional
chondrosarcoma components were graded according
to Evans. One tumour was grade I (case 2), two were
grade II (cases 4 and 5), and two were grade III
(cases 1 and 3). The clear cell components were com-
posed of cells with abundant eosinophilic to clear
cytoplasm with distinct membranes. Overall, nuclei
were round and centrally located, with a prominent
central nucleolus (Figure 2A). Areas of atypia were
occasionally observed, and ranged from cells with
slightly enlarged, hyperchromatic nuclei to cells with
bizarre and monstrous nuclei (Figure 2B–F). The
degree of atypia varied between cases, and was most
prominent in case 3. Furthermore, tumour cells were
admixed with a regular deposition of trabeculae of
woven bone, and numerous osteoclast-like giant cells.
The amount of clear cell chondrosarcoma areas var-
ied between cases, and ranged between 5% and 20%.
Noticeably, these areas were scattered throughout the
specimens and did not show abrupt transition, but
rather merged with the conventional chondrosar-
coma components (Figure 3).
M O L E C U L A R A N A L Y S I S
Molecular analysis of the conventional chondrosar-
coma component for IDH1 and IDH2 was possible in
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 75, 843–852.
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all cases. IDH1 mutations were found in three
cases, i.e. IDH1 c.395G>T, p.(Arg132Leu) in case 1
(Figure 4) and case 5, and IDH1 c.394C>T,
p.(Arg132Cys) in case 3. Cases 2 and 4 showed no
IDH mutation. The clear cell counterpart of IDH
mutant conventional chondrosarcoma could be
evaluated in all three cases. Case 3 showed subopti-
mal sequence metrics, and analysis was therefore
repeated. All samples showed identical IDH muta-
tions. Molecular analysis for H3F3B was performed
for cases 1 and 3, and showed no mutation.
Additional mutations in TP53 c.536A>G,
p.(His179Arg) were found in both components of
case 3 (Table 1).
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemistry for H3K27me3, H3F3B K36M
and p53 was performed for both components.
Because a recent publication showed deficiency of
H3K27me3 in a subset of dedifferentiated chon-
drosarcomas,16 immunohistochemical analysis of
H3K27me3 was performed to rule out this possibility.
No case showed loss of expression. No tumour
showed positive staining for H3F3B K36M, whereas
the external control was positive. In case 3, immuno-
histochemistry for p53 showed, in both components,
a mutant staining pattern (Figure 5), whereas in the
remaining cases a wild-type staining pattern was
observed.
Discussion
In this article, we present the clinical and histopatho-
logical characteristics of five cases in which we
observed clear cell chondrosarcoma areas adjacent to
conventional chondrosarcoma. Molecular and
immunohistochemical analyses were performed to
investigate whether these hybrid tumours should be
considered to be part of a collision tumour, a conven-
tional chondrosarcoma with clear cell change, or
clear cell chondrosarcoma with extensive areas of
conventional chondrosarcoma.
Clear cell chondrosarcoma was first described by
Unni et al. in 1976,1 and it has been noticed that
these tumours may contain areas of conventional
low-grade chondrosarcoma. This tumour has low
malignant potential, and en-bloc resection with clear
margins is usually curative.1,2,17 Whereas IDH1 and
IDH2 mutations can be encountered in ~50% of con-
ventional chondrosarcomas,6 IDH mutations are
absent in clear cell chondrosarcoma.8,9 Recently, an
H3F3B p.K36M mutation, which is typically found in
chondroblastoma of bone,10 was found in one clear
cell chondrosarcoma.18 Although conventional chon-
drosarcoma may show a variety of histological fea-
tures, depending on histological grade, there are, as
yet, no reports of conventional chondrosarcoma
admixed with areas of clear cell chondrosarcoma fea-
tures in the literature, to the best of our knowledge.
Histopathological analysis of the five cases revealed a
A B
Figure 1. A, Magnetic resonance imaging of case 1. A coronal T2 SPIR sequence of the right knee shows a multiloculated lesion in the prox-
imal tibia epimetaphysis. The lesion contains T2 hyperintense cartilage nodules, which are typical for chondroid tumours. The extension into
the epiphysis (in this case up to the subchondral bone plate) is not typical for a chondroid tumour, which is usually contained in the meta-
physis. Small internal foci of low signal intensity are noted, and are in keeping with chondroid matrix calcifications. Perilesional bone mar-
row oedema and soft tissue oedema are present. B, Magnetic resonance imaging of case 2. Axial T1 SPAIR after administration of
gadolinium contrast in the left distal femur shows a typical septonodular or ‘rings-and-arcs’ enhancement in this cartilaginous tumour. The
lesion extends into the epiphysis and through the posterior cortex into the soft tissues. Perilesional bone marrow oedema is present.
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 75, 843–852.
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tumour configuration consisting of 5–20% of clear
cell chondrosarcoma areas with variable degree of
atypia, gradually merging with the conventional
chondrosarcoma component. Furthermore, four of
the five tumours were located at the predilection sites
for conventional chondrosarcoma, and behaved as
would be expected on the basis of histological grade
of the conventional chondrosarcoma component.
Also, identical IDH and TP53 mutations were present
in both components of case 3. In two cases, conven-
tional chondrosarcoma areas lacked IDH mutations,
which could be expected, given the frequency of IDH
mutations in conventional chondrosarcoma,6 and
none of the cases showed an H3F3B mutation. The
MRI characteristics in four of the five cases were in
keeping with conventional chondrosarcoma, and did
not show a separate clear cell chondrosarcoma com-
ponent within the tumours. In case 2, the epiphyseal
location of the tumour was the only finding that
pointed towards clear cell chondrosarcoma. Our
results therefore suggest that clear cell chondrosar-
coma areas in conventional chondrosarcoma
A B
C D
E F
Figure 2. Clear cell chondrosarcoma areas with variable degrees of nuclear atypia. A, Clear cells are admixed with trabeculae of woven
bone, resembling clear cell chondrosarcoma. Areas with large clear cells with distinct cytoplasmic membranes are encountered in most
cases. Nuclei are small, regular, and without prominent atypia (case 1). B–D, Cells with slightly enlarged and hyperchromatic nuclei can be
present (case 2, case 4, and case 5, respectively). Note the regular deposition of woven bone that is characteristic of clear cell chondrosar-
coma. E, Severe atypia can be seen. Cells with enlarged, irregular and hyperchromatic nuclei are admixed with woven bone and osteoclast-
like giant cells (case 3). F, Occasionally, cells with bizarre and monstrous nuclei are distributed between more typical cells with round nuclei
and prominent nucleoli, surrounded by abundant eosinophilic cytoplasm (case 3). Scale bar: 50 lm (A–E), 100 lm (F).
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 75, 843–852.
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represent a morphological phenomenon, rather than
a collision between two tumour types or clear cell
chondrosarcoma with extensive areas of conventional
chondrosarcoma. An exact cut-off of the volume of
the clear chondrosarcoma-like component within
conventional chondrosarcoma can only be deter-
mined when more cases are presented after more
awareness has been raised.
Importantly, the presence of woven bone within
the clear cell areas combined with features of a
A B
Figure 3. A, Haphazardly arranged areas with clear cell chondrosarcoma morphology and conventional chondrosarcoma. B, At high power,
both components gradually merge together, as opposed to dedifferentiated chondrosarcoma (case 1). Scale bar: 250 lm (A), 100 lm (B).
A B
C D
Figure 4. A, Microdissected clear cell chondrosarcoma area used for next-generation sequencing (NGS). B, NGS showing the presence of the
IDH1 c.395G>T, p.Arg132Leu mutation (allele frequency: 0.03). C, Microdissected conventional chondrosarcoma area used for NGS. D, NGS
showing the presence of an identical IDH1 c.395G>T, p.Arg132Leu mutation (allele frequency: 0.29) (case 1). Scale bar: 250 lm (A,C).
Clear cell change in conventional chondrosarcoma 849
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cartilage tumour can mislead the pathologist. In ded-
ifferentiated chondrosarcoma, areas with neoplastic
bone formation can be seen. The architectural com-
position should be discriminating in these cases: in
dedifferentiated chondrosarcoma an abrupt transition
is seen between both components,19 whereas in the
current cases clear cell chondrosarcoma areas gradu-
ally merge with conventional chondrosarcoma areas.
Also, in dedifferentiated chondrosarcoma the dediffer-
entiated component clearly shows high-grade fea-
tures, whereas the present cases have a very specific
clear cell chondrosarcoma morphology with variable
nuclear atypia. Recently, loss of H3K27me3 was
described in 32% of dedifferentiated chondrosarco-
mas, and was restricted to the dedifferentiated compo-
nent.16 In the present series, all cases showed
retention of H3K27me3 in the clear cell areas, which
is in support of these tumours not belonging to this
distinct subset of dedifferentiated chondrosarcomas
with H3K27me3 deficiency.
Similarly, on the basis of the presence of bone for-
mation, chondroblastic osteosarcoma can also enter
the differential diagnosis. The presence of conven-
tional chondrosarcoma areas with limited nuclear
atypia should lead to the correct diagnosis, because,
in chondroblastic osteosarcoma, the nuclear atypia in
the cartilaginous areas is usually abundant. More-
over, the trabeculae in clear cell chondrosarcoma
show osteoblastic rimming, and this is usually much
more regular and ‘rhythmic’ than the more irregular
deposition in chondroblastic osteosarcoma. The dis-
tinction can be challenging, but is crucial, as high-
grade osteosarcoma requires different treatment.20
Molecular analysis of IDH can be helpful, as the pres-
ence of this mutation strongly favours chondrosar-
coma over chondroblastic osteosarcoma.21
It should be noted that the sequence metrics of
case 3 were suboptimal, owing to a long period of
decalcification with formic acid, but identical IDH1
and TP53 mutations were found in both components,
also after repetition of NGS. It is of note that the
allele frequency of IDH mutant reads was relatively
low in clear cell areas, as compared with areas with
conventional chondrosarcoma and as compared with
A B
C D
Figure 5. p53 immunohistochemistry (case 3). A, Clear cell chondrosarcoma component. B, Immunohistochemistry for p53 in the same
tumour region shows overexpression in the tumour cells. C, Conventional chondrosarcoma area. D, Immunohistochemistry for p53 shows
overexpression in the tumour cells. Scale Bar: 50 lm (A–D).
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the TP53 variant. Therefore, we cannot completely
rule out the possibility that the clear cell chondrosar-
coma area lacks the IDH mutation. Unfortunately, for
this specific mutation, no antibody is available for
immunohistochemical confirmation.22 An explana-
tion for the low allele frequency could be the higher
contamination with normal cells. Even though we
used microdissection, the clear cell chondrosarcoma
areas were scattered throughout the specimen, and
tumour cells were intermingled with giant cells and
stromal cells, which may have decreased the allele
frequency in the clear cell chondrosarcoma areas as
compared with the more homogeneous conventional
chondrosarcoma areas. Also, as heterogeneity can
often be present in tumours,23 this can contribute to
the lower allele frequency in the clear cell compo-
nent. The fact that we confirmed the presence of p53
overexpression by using p53 immunohistochemistry
in both components of case 3 further supports the
clonal relationship between the clear cell chondrosar-
coma and the conventional chondrosarcoma areas.
Although, in our experience, conventional chon-
drosarcoma areas constitute a minor component of
clear cell chondrosarcoma, no exact percentages for
the amount of conventional chondrosarcoma areas
within clear cell chondrosarcoma are available.1,2
Therefore, we cannot completely rule out the possibil-
ity that the two IDH wild-type cases represent clear
cell chondrosarcoma with an abundant conventional
chondrosarcoma component. This is especially rele-
vant for case 2, as it involved a young patient with
an epiphyseal tumour with a low-grade chondrosar-
coma component. The radiology of case 4 was more
in line with conventional chondrosarcoma, and high-
grade (grade II) conventional chondrosarcoma was
morphologically encountered. As no specific molecu-
lar alterations have been reported in clear cell chon-
drosarcoma, at present this issue cannot be further
resolved.
In conclusion, we report five cases of conven-
tional chondrosarcoma with clear cell chondrosar-
coma features, in which additional clinical,
histopathological and molecular characterisation of
both components suggest that this represents a mor-
phological phenomenon. Clear cell chondrosarcoma
features are rarely encountered in conventional
chondrosarcoma, but should not prevent the pathol-
ogist from establishing the diagnosis of conventional
chondrosarcoma. Most importantly, these lesions
should not be confused with clear cell chondrosar-
coma, dedifferentiated chondrosarcoma, or chon-
droblastic osteosarcoma, as treatment and outcome
differ significantly.
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